On our screens:Stocks that buy back more than they dilute
Is the price fair?
What TMO's price assumes
Thermo Fisher Scientific trades at 32.5× earnings against 33.6× for the median Diagnostics & Research name, cheaper than its own group.
32.5
Trailing P/E · Diagnostics & Research median 33.6 · cheaper than the typical name in its group
- Price / sales
- 3.90
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.2%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +7.8%
Growth the price implies · The price pays for +7.8% free cash flow growth a year for a decade; the business has delivered +7.7% a year over the last three.
Details›
- Price / book2026-Q1
- 3.40
- EV / EBIT2026-Q1
- 27.4
- EV / sales2026-Q1
- 4.78
- Healthcare median P/E362 names
- 29.9
- Diagnostics & Research median P/E29 names
- 33.6
- Free cash flow, trailing twelve months
- $7.32B
- Market capitalisation
- $172.7B
- 3-year revenue growth
- +2.1%
- 3-year free cash flow growth
- +7.7%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $534.57 |
| Its own P/E history, median | $600.12 |
| Its own P/E history, upper quartile | $630.79 |
| 52-week range | $437.90 – $638.18 |
| Today | $603.18 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
The closest names by size in the same industry